semaglutide permanent side effects Comparative safety and of and tirzepatide: Implications for clinical decision-making in obesity management Semaglutide for Chronic Weight Management

Pathophysiology of RAGE in inflammatory diseases

25 mg/day oral Tirzepatide 15 mg/week Retatrutide 12 mg/week Liraglutide 3.0 mg/day Factor Peak trial weight loss Semaglutide -14.9% at 68 wks (STEP 1) Tirzepatide -22.5% at 72 wks (SURMOUNT-1) Retatrutide -28.7% at 68 wks (TRIUMPH-4) Liraglutide -8% at 56 wks (SCALE) Factor FDA status (June 2026) Semaglutide Approved (T2D, obesity, CVD, MASH, CKD, oral) Tirzepatide Approved (T2D, obesity) Retatrutide Investigational - Phase 3 Liraglutide Approved (Saxenda obesity, Victoza T2D) Factor CV outcomes data Semaglutide Yes - SELECT (20% MACE drop) Tirzepatide SURPASS-CVOT ongoing Retatrutide TRIUMPH-3 ongoing Liraglutide Yes - LEADER (13% MACE drop) These compounds are not interchangeable

suppresses TGF--driven fibrosis and cardiac/renal remodeling: PMC4889319

Blood sugar levels can be affected by stress, illness, surgery, exercise, alcohol use, medications, or skipping meals

Treatment at these early stages usually involves surgery to remove the affected portion of the colon

Track your protein: Ensure you aren't accidentally dipping below your requirements as your appetite changes